摘要 |
A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to "ATR-101") suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome. |
申请人 |
MILLENDO THERAPEUTICS, INC.;MATUNAS, ROBERT;CHEN, HERMAN;BETANCOURT, AIMESTHER;UZARAMA, CHARLES;THIBERT, ROCH |
发明人 |
MATUNAS, ROBERT;CHEN, HERMAN;BETANCOURT, AIMESTHER;UZARAMA, CHARLES;THIBERT, ROCH;HUNT, STEPHEN, WARREN, III;PHILLIPS, MARTIN, DOUGLAS |